Home / Health / Melanoma Trial Doses First Patients
Melanoma Trial Doses First Patients
3 Aug
Summary
- Diakonos Oncology's DOC1021 trial for refractory melanoma has dosed its first patients.
- The trial is assessing safety, immune activity, and efficacy in non-responsive melanoma patients.
- Initial patient treatments have shown no significant acute adverse events.
Diakonos Oncology has dosed the initial patients in its Phase I/II DOC-RM clinical trial, evaluating DOC1021 (dubodencel) for refractory melanoma. This significant step was taken at prominent US medical centers, including City of Hope in California and the University of Alabama at Birmingham.
The multicenter trial aims to assess the safety profile, immune response, and preliminary clinical effectiveness of DOC1021. It specifically targets patients diagnosed with unresectable or metastatic melanoma who have not responded to previous treatments, notably including anti-programmed cell death protein 1 (PD-1) therapy.
Patients enrolled in the study are administered two courses of DOC1021 alongside pegylated interferon, with an option for a booster dose. Key trial endpoints include evaluating safety, objective response rates, circulating tumor DNA levels, and analyzing immune biomarkers from both tumor tissue and blood samples.
Early results from the first patients treated have been positive, with no significant acute adverse events reported. This outcome is consistent with Diakonos Oncology's prior clinical work in glioblastoma and pancreatic cancer, providing a hopeful outlook for the current trial. The company anticipates reporting initial preliminary results from the DOC-RM trial by the end of 2026. The DOC1021 drug previously received Fast Track Designation from the US FDA in May 2026 for unresectable or metastatic cutaneous melanoma.
